Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Bewersdorf JP, Zeidan AM. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers 2021, 13: 1610. PMID: 33807279, PMCID: PMC8036734, DOI: 10.3390/cancers13071610.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic myelomonocytic leukemiaMyelodysplastic syndromeMyelomonocytic leukemiaAllogeneic hematopoietic cell transplantRed blood cell transfusionClinical symptom burdenLR-MDS patientsOverall survival benefitBlood cell transfusionHematopoietic cell transplantHigh-risk patientsMainstay of therapyErythropoiesis-stimulating agentsRisk of progressionRisk stratification toolIndividualized treatment strategiesAcute myeloid leukemiaRoutine clinical useAgent azacitidineAllo-HCTCell transfusionMost patientsSupportive careSurvival benefitSymptom burdenClinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
Lewis R, Bewersdorf JP, Zeidan AM. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management And Research 2021, 13: 645-657. PMID: 33531837, PMCID: PMC7846829, DOI: 10.2147/cmar.s240600.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLower-risk myelodysplastic syndromesErythropoiesis-stimulating agentsTherapeutic optionsSymptomatic anemiaMyelodysplastic syndromeRed blood cell transfusionFurther therapeutic optionsBlood cell transfusionAvailable therapeutic optionsMajority of patientsManagement of anemiaPrimary clinical goalQuality of lifeResultant cytopeniasCell transfusionFrequent transfusionsImmunosuppressive therapyClinical improvementMost patientsSelect patientsTransfusion burdenClinical managementIron overloadNovel agentsAdditional therapeutics